首页|益生菌联合四联疗法治疗青年人群幽门螺杆菌感染的临床疗效分析

益生菌联合四联疗法治疗青年人群幽门螺杆菌感染的临床疗效分析

扫码查看
目的 分析益生菌联合四联疗法对青年人群幽门螺杆菌感染的治疗效果。方法 90 例幽门螺杆菌感染的青年患者,按照门诊就诊顺序分为对照组和观察组,每组 45 例。对照组用标准四联疗法治疗,观察组在对照组基础上联合使用益生菌治疗。对比两组幽门螺杆菌根除率、血清炎症因子、免疫功能、肠道菌群和胃蛋白酶原水平。结果 观察组幽门螺杆菌根除率为 91。11%(41/45),明显高于对照组的 71。11%(32/45),两组数据差异明显(P<0。05);用药后,两组患者C反应蛋白、肿瘤坏死因子-α和白细胞介素-6 水平下降,观察组C反应蛋白(6。24±1。36)mg/L、肿瘤坏死因子-α(121。24±22。18)pg/ml、白细胞介素-6(5。54±1。12)pg/ml较对照组的(9。32±1。16)mg/L、(178。21±20。56)pg/ml、(8。16±1。27)pg/ml更低(P<0。05)。用药后,两组CD4+、CD4+/CD8+水平上升,CD8+水平下降,观察组CD4+(48。32±2。78)%、CD4+/CD8+(1。56±0。15)高于对照组的(46。21±3。54)%、(1。32±0。12),CD8+(33。18±1。68)%低于对照组的(35。78±1。56)%(P<0。05)。用药后,两组双歧杆菌和乳酸杆菌数目上升,肠球菌和肠杆菌数目下降,观察组双歧杆菌(9。60±0。72)CFU/g、乳酸杆菌(9。78±0。56)CFU/g高于对照组的(8。44±0。81)、(8。54±0。48)CFU/g,肠球菌(7。12±1。16)CFU/g、肠杆菌(7。18±0。72)CFU/g低于对照组的(8。44±1。18)、(8。24±1。12)CFU/g(P<0。05)。用药后,观察组胃蛋白酶原Ⅰ(112。21±1。72)μg/L、胃蛋白酶原Ⅰ/胃蛋白酶原Ⅱ(11。15±0。74)较对照组的(88。56±1。78)μg/L、(6。78±0。73)更高,胃蛋白酶原Ⅱ(10。06±2。32)μg/L较对照组的(11。12±2。44)μg/L更低(P<0。05)。结论 予以幽门螺杆菌感染青年患者益生菌联合四联疗法治疗,可有效清除幽门螺杆菌,调节炎症因子和肠道菌群、改善免疫功能作用明显,对胃蛋白酶原水平有调节作用,可推广。
Analysis of the clinical efficacy of probiotics plus quadruple therapy for Helicobacter pylori infection in a young population
Objective To analyze the therapeutic effect of probiotics combined with quadruple therapy on Helicobacter pylori infection in a young population.Methods 90 young patients with Helicobacter pylori infection were grouped into a control group and an observation group according to the order of outpatients visits,with 45 cases in each group.The control group used quadruple therapy,and the observation group used probiotics on the basis of the control group.The eradication rate of Helicobacter pylori,serum inflammatory factors,immune function,intestinal flora and pepsinogen levels were compared between the two groups.Results The eradication rate of Helicobacter pylori in the observation group was 91.11%(41/45),which was higher than 71.11%in the control group,and the difference between the two groups was significant(P<0.05).After medication,the levels of C-reactive protein,tumor necrosis factor-α and interleukin-6 in both groups were decreased;the C-reactive protein in the observation group was(6.24±1.36)mg/L,the tumor necrosis factor-α was(121.24±22.18)pg/ml,and the interleukin-6 was(5.54±1.12)pg/ml,which were lower than(9.32±1.16)mg/L,(178.21±20.56)pg/ml,and(8.16±1.27)pg/ml in the control group(P<0.05).After medication,the levels of CD4+,CD4+/CD8+ increased,and CD8+ decreased in both groups;the observation group had CD4+ of(48.32±2.78)%and CD4+/CD8+ of(1.56±0.15),which were higher than(46.21±3.54)%and(1.32±0.12)in the control group;and CD8+ of(33.18±1.68)%was lower than(35.78±1.56)%in the control group(P<0.05).After medication,the numbers of bifidobacterium and lactobacillus increased,while the numbers of enterococcus and enterobacter decreased in both groups;the numbers of bifidobacterium and lactobacillus were(9.60±0.72)and(9.78±0.56)CFU/g in the observation group,which were higher than(8.44±0.81)and(8.54±0.48)CFU/g in the control group;the numbers of enterococcus and enterobacter were(7.12±1.16)and(7.18±0.72)CFU/g in the observation group,which were lower than(8.44±1.18)and(8.24±1.12)CFU/g in the control group(P<0.05).After medication,the levels of pepsinogen Ⅰ and pepsinogen Ⅰ/Ⅱ were(112.21±1.72)μg/L and(11.15±0.74)in the observation group,which were higher than(88.56±1.78)μg/L and(6.78±0.73)in the control group;the pepsinogen Ⅱ of(10.06±2.32)μg/L was lower than(11.12±2.44)μg/L in the control group(P<0.05).Conclusion The combination of probiotics and quadruple therapy in young patients with Helicobacter pylori infection can effectively remove Helicobacter pylori,regulate inflammatory factors and intestinal flora,improve immune function,and have a regulatory effect on pepsinogen levels,which can be promoted.

ProbioticsQuadruple therapyHelicobacter pylori infectionInflammatory factorsImmune functionIntestinal floraPepsinogen

周月珠

展开 >

350000 福州市台江区茶亭街道社区卫生服务中心

益生菌 四联疗法 幽门螺杆菌感染 炎症因子 免疫功能 肠道菌群 胃蛋白酶原

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(3)
  • 20